1
|
Wang J, Xiang C, Cai Y, Mei Z, Lu Q, Liu B, Zou L. Clinicopathological and prognostic significance of COX-2 in glioma patients: a meta-analysis. ARQUIVOS DE NEURO-PSIQUIATRIA 2022; 80:1254-1261. [PMID: 36580964 PMCID: PMC9800163 DOI: 10.1055/s-0042-1758864] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
BACKGROUND In recent years, cyclooxygenase-2 (COX-2) has been identified as a cancer stem cell (CSC) marker in gliomas. Nevertheless, the clinical and prognostic significance of COX-2 in glioma patients remains controversial. OBJECTIVE To evaluate the correlation of COX-2 with the prognosis in glioma patients. METHODS Eligible studies on this subject were included, and pooled odd ratios (ORs) and hazard ratios (HRs) with 95% confidence intervals (95%CIs) were estimated. Publication bias was assessed through funnel plots, and heterogeneity and sensitivity were analyzed as well. RESULTS In the present study, 11 articles with a total of 641 patients were included. The high expression of COX-2 in glioma patients was negatively associated with overall survival (OS) (n = 11; HR = 2.26; 95%CI = 1.79-2.86), and the subgroup analysis showed no differences in OS between Asian (n = 5; HR = 2.16; 95%CI = 1.57-2.97) and non-Asian (n = 6; HR = 2.39; 95%CI = 1.69-3.38) glioma patients. The Begg funnel plots test indicated that there was no evident risk of publication bias in the meta-analysis. CONCLUSION The present study suggests that COX-2 could be recommended as a useful pathological and prognostic biomarker in the clinical practice.
Collapse
Affiliation(s)
- Jun Wang
- China Three Gorges University, The People's Hospital, Yichang, Hubei Province, China.
| | - Chenyan Xiang
- China Three Gorges University, The People's Hospital, Yichang, Hubei Province, China.
| | - Yi Cai
- China Three Gorges University, College of Basic Medical Sciences, Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy, Yichang, Hubei, China.,China Three Gorges University, College of Basic Medical Sciences, The Institute of Infection and Inflammation, Yichang, China.
| | - Ziyi Mei
- China Three Gorges University, College of Basic Medical Sciences, Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy, Yichang, Hubei, China.,China Three Gorges University, College of Basic Medical Sciences, The Institute of Infection and Inflammation, Yichang, China.
| | - Qianqian Lu
- China Three Gorges University, College of Basic Medical Sciences, Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy, Yichang, Hubei, China.,China Three Gorges University, College of Basic Medical Sciences, The Institute of Infection and Inflammation, Yichang, China.
| | - Binbin Liu
- China Three Gorges University, College of Basic Medical Sciences, Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy, Yichang, Hubei, China.,China Three Gorges University, College of Basic Medical Sciences, The Institute of Infection and Inflammation, Yichang, China.
| | - Lili Zou
- China Three Gorges University, College of Basic Medical Sciences, Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy, Yichang, Hubei, China.,China Three Gorges University, College of Basic Medical Sciences, The Institute of Infection and Inflammation, Yichang, China.,Address for correspondence Lili Zou
| |
Collapse
|
2
|
Kawamoto H, Hara H, Araya J, Ichikawa A, Fujita Y, Utsumi H, Hashimoto M, Wakui H, Minagawa S, Numata T, Arihiro S, Matsuura T, Fujiwara M, Ito S, Kuwano K. Prostaglandin E-Major Urinary Metabolite (PGE-MUM) as a Tumor Marker for Lung Adenocarcinoma. Cancers (Basel) 2019; 11:cancers11060768. [PMID: 31163629 PMCID: PMC6627988 DOI: 10.3390/cancers11060768] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/09/2019] [Revised: 05/19/2019] [Accepted: 05/30/2019] [Indexed: 01/20/2023] Open
Abstract
Background: Prostaglandin E2 (PGE2) is metabolized to prostaglandin E-major urinary metabolite (PGE-MUM). Enhanced cyclooxygenase-2 (COX-2) expression demonstrated in lung adenocarcinoma indicates increased PGE-MUM levels in patients with lung adenocarcinoma. Objectives: We aimed to elucidate the clinical usefulness of measuring PGE-MUM as an indicator of tumor burden in patients with lung adenocarcinoma. Methods: PGE-MUM was measured by a radioimmunoassay in control healthy volunteers (n = 124) and patients with lung adenocarcinoma (n = 54). Associations between PGE-MUM levels and clinical characteristics of the patients (including lung cancer stage and TNM factors (T: Tumor, N: Node, M: Metastasis) were examined. Results: PGE-MUM levels were significantly elevated in patients with lung adenocarcinoma. A PGE-MUM level of 14.9 μg/g∙Cr showed 70.4% sensitivity and 67.7% specificity for the diagnosis of lung adenocarcinoma. PGE-MUM levels tended to be positively correlated with cancer progression as determined by the TNM staging system. Advanced stage (stage III, stage IV, and recurrence) was significantly associated with high PGE-MUM levels by logistic regression analysis. No apparent correlation was demonstrated between PGE-MUM and carcinoma embryonic antigen (CEA) levels. Conclusions: PGE-MUM can be a promising biomarker reflecting the systemic tumor burden of lung adenocarcinoma.
Collapse
Affiliation(s)
- Hironori Kawamoto
- Division of Respiratory diseases, Department of Internal Medicine, School of Medicine, Jikei University, Tokyo 105-8471, Japan.
| | - Hiromichi Hara
- Division of Respiratory diseases, Department of Internal Medicine, School of Medicine, Jikei University, Tokyo 105-8471, Japan.
| | - Jun Araya
- Division of Respiratory diseases, Department of Internal Medicine, School of Medicine, Jikei University, Tokyo 105-8471, Japan.
| | - Akihiro Ichikawa
- Division of Respiratory diseases, Department of Internal Medicine, School of Medicine, Jikei University, Tokyo 105-8471, Japan.
| | - Yu Fujita
- Division of Respiratory diseases, Department of Internal Medicine, School of Medicine, Jikei University, Tokyo 105-8471, Japan.
| | - Hirofumi Utsumi
- Division of Respiratory diseases, Department of Internal Medicine, School of Medicine, Jikei University, Tokyo 105-8471, Japan.
| | - Mitsuo Hashimoto
- Division of Respiratory diseases, Department of Internal Medicine, School of Medicine, Jikei University, Tokyo 105-8471, Japan.
| | - Hiroshi Wakui
- Division of Respiratory diseases, Department of Internal Medicine, School of Medicine, Jikei University, Tokyo 105-8471, Japan.
| | - Shunsuke Minagawa
- Division of Respiratory diseases, Department of Internal Medicine, School of Medicine, Jikei University, Tokyo 105-8471, Japan.
| | - Takanori Numata
- Division of Respiratory diseases, Department of Internal Medicine, School of Medicine, Jikei University, Tokyo 105-8471, Japan.
| | - Seiji Arihiro
- Division of Gastroenterology and Hepatology, Department of Internal Medicine, School of Medicine, Jikei University, Tokyo 105-8471, Japan.
| | - Tomokazu Matsuura
- Department of Laboratory Medicine, School of Medicine, Jikei University, Tokyo 105-8471, Japan.
| | - Mutsunori Fujiwara
- Department of Clinical Pathology, Japanese Red Cross Medical Center, Tokyo 150-8935, Japan.
| | - Satoru Ito
- IDAC Theranostics, Inc.; Tokyo 113-0033, Japan.
| | - Kazuyoshi Kuwano
- Division of Respiratory diseases, Department of Internal Medicine, School of Medicine, Jikei University, Tokyo 105-8471, Japan.
| |
Collapse
|
3
|
Wang S, Gao H, Zuo J, Gao Z. Cyclooxygenase-2 expression correlates with development, progression, metastasis, and prognosis of osteosarcoma: a meta-analysis and trial sequential analysis. FEBS Open Bio 2019; 9:226-240. [PMID: 30761249 PMCID: PMC6356183 DOI: 10.1002/2211-5463.12560] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2018] [Revised: 10/16/2018] [Accepted: 11/07/2018] [Indexed: 11/12/2022] Open
Abstract
Cyclooxygenase‐2 (COX‐2), a key enzyme in arachidonic acid metabolism, is involved in several cancers, including osteosarcoma. The prognostic significance of COX‐2 in osteosarcoma remains controversial. This study was to analyze the potential clinical and prognostic effects of COX‐2 protein expression in patients with osteosarcoma. Eligible articles were searched via online databases. The combined odds ratios (ORs) or hazard ratios (HRs) with their 95% confidence intervals (95% CIs) were calculated using the random‐effects model. Trial sequential analysis (TSA) was applied to analyze the required information size and determine the reliability of the evidence. Twenty‐three studies on COX‐2 expression were identified, which included a total of 1084 patients with malignant osteosarcoma and 247 patients with benign osteochondroma. COX‐2 protein expression in osteosarcoma was higher than in benign osteochondroma (OR = 7.66, P < 0.001). COX‐2 expression was not correlated with age, gender, tumor location, cancer histology, or necrosis (P > 0.1), but was significantly associated with tumor grade (high grade vs. low grade: OR = 4.81, P < 0.001), clinical stage (stage 3–4 vs. stage 1–2: OR = 4.89, P < 0.001), and metastasis (yes vs. no: OR = 3.53, P < 0.001). Based on TSA results, we suggest that additional studies are not required to examine osteosarcoma vs. benign osteochondroma, tumor grade, clinical stage, or metastasis. No heterogeneity was observed in these analyses. COX‐2 expression is linked to poor prognosis in metastasis‐free survival, overall survival, and relapse‐free survival, as indicated by multivariate analysis. Therefore, the expression of COX‐2 may correlate with the development, progression, metastasis, and poor prognosis of osteosarcoma.
Collapse
Affiliation(s)
- Shengqun Wang
- Orthopaedics China-Japan Union Hospital of Jilin University China
| | - Hongwei Gao
- Orthopaedics The Affiliated Hospital to Changchun University of Chinese Medicine Jilin China
| | - Jianlin Zuo
- Orthopaedics China-Japan Union Hospital of Jilin University China
| | - Zhongli Gao
- Orthopaedics China-Japan Union Hospital of Jilin University China
| |
Collapse
|
4
|
Sun J, Qiao Y, Song T, Wang H. MiR‑495 suppresses cell proliferation by directly targeting HMGA2 in lung cancer. Mol Med Rep 2018; 19:1463-1470. [PMID: 30569167 PMCID: PMC6390076 DOI: 10.3892/mmr.2018.9773] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2018] [Accepted: 10/01/2018] [Indexed: 12/28/2022] Open
Abstract
The present study aimed to investigate the expression of microRNA-495 (miR-495) in non-small cell lung cancer (NSCLC) tissues and cells, as well as its function on the proliferation of lung cancer cells. The expression of miR-495 in 122 pairs of NSCLC tissues and matched paracarcinoma tissues, as well as in human lung cancer cell lines (A549, H460, H1650, H520 and SK-MES-1) and the normal human pulmonary bronchial epithelial cell line 16HBE was determined using reverse transcription quantitative polymerase chain reaction (RT-qPCR). As predicted by bioinformatics analysis, high mobility group A2 (HMGA2) may be a potential target gene of miR-495. In addition, the regulatory function of miR-495 on its target gene HMGA2 was evaluated using a dual-luciferase reporter assay, RT-qPCR and western blotting. Furthermore, the effect of miR-495 on the proliferation of A549 lung cancer cells was investigated using a Cell Counting Kit-8 (CCK-8) assay. The results demonstrated that the expression of miR-495 in NSCLC tissues and cells was significantly downregulated compared with the control. In addition, downregulated expression of miR-495 was associated with tumor differentiation, lymph node metastasis and tumor, node and metastasis staging. Additionally, a dual-luciferase reporter assay revealed that miR-495 could directly associated with the 3′-untranslated region of HMGA2. Upregulated expression of miR-495 significantly downregulated the mRNA and protein expression levels of HMGA2 in A549 cells. Furthermore, the results of CCK-8 assay revealed that upregulated expression of miR-495 significantly suppressed the proliferation of A549 cells; HMGA2 overexpression reversed this inhibition. In summary, the findings of the present study demonstrated that miR-495 was downregulated in NSCLC tissues and cells. In addition, miR-495 suppressed the proliferation of lung cancer cells by directly targeting HMGA2.
Collapse
Affiliation(s)
- Jiangtao Sun
- Department of Oncology, Weihai Central Hospital, Weihai, Shandong 264400, P.R. China
| | - Yanping Qiao
- Department of Hematology, Weihai Central Hospital, Weihai, Shandong 264400, P.R. China
| | - Tao Song
- Department of Endocrinology, Weihai Central Hospital, Weihai, Shandong 264400, P.R. China
| | - Haiwen Wang
- Department of Cardio‑Thoracic Surgery, Weihai Central Hospital, Weihai, Shandong 264400, P.R. China
| |
Collapse
|
5
|
Moraes JL, Moraes AB, Aran V, Alves MR, Schluckbier L, Duarte M, Toscano E, Zamboni M, Sternberg C, de Moraes E, Lapa E Silva JR, Ferreira CG. Functional analysis of polymorphisms in the COX-2 gene and risk of lung cancer. Mol Clin Oncol 2017; 6:494-502. [PMID: 28413655 PMCID: PMC5374939 DOI: 10.3892/mco.2017.1167] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2016] [Accepted: 01/31/2017] [Indexed: 12/20/2022] Open
Abstract
The enzyme cyclooxygenase 2 (COX-2) is known to be involved in tumorigenesis and metastasis in certain types of cancer. Nevertheless, the prognostic value of COX-2 overexpression and its polymorphisms in patients with non-small cell lung cancer (NSCLC) have yet to be fully elucidated. The aim of the present study was to investigate the association between the three most commonly studied COX-2 gene polymorphisms (-1195 G/A, -765 G/C and 8473 T/C) with COX-2 expression and lung cancer risk in a Brazilian cohort. In the present hospital based, case-control retrospective study, 104 patients with NSCLC and 202 cancer free control subjects were genotyped for -1195 G/A, -765 G/C and 8473 T/C polymorphisms using allelic discrimination with a reverse transcription quantitative polymerase chain reaction method. COX-2 mRNA expression was analyzed in surgically resected tumors from 34 patients with NSCLC. The results revealed that COX-2 expression levels were higher in tumor tissue compared with normal lung tissue. However, this overexpression of COX-2 was not associated with the patient outcome, and furthermore, none of the analyzed polymorphisms were associated with the risk of developing lung cancer, COX-2 overexpression, or the overall survival of the patients with NSCLC. Taken together, the findings described in the present study do not support a major role for COX-2 polymorphisms and COX-2 overexpression in lung carcinogenesis within the Brazilian population.
Collapse
Affiliation(s)
- Joyce L Moraes
- Clinical Research Division, Brazilian National Cancer Institute (INCA), Rio de Janeiro, Brazil
| | - Amanda B Moraes
- Clinical Research Division, Brazilian National Cancer Institute (INCA), Rio de Janeiro, Brazil
| | - Veronica Aran
- Clinical Research Division, Brazilian National Cancer Institute (INCA), Rio de Janeiro, Brazil
| | - Marcelo R Alves
- Evandro Chagas Clinical Research Institute, Oswaldo Cruz Foundation (FIOCRUZ), Rio de Janeiro, Brazil
| | - Luciene Schluckbier
- Clinical Research Division, Brazilian National Cancer Institute (INCA), Rio de Janeiro, Brazil
| | - Mariana Duarte
- Clinical Research Division, Brazilian National Cancer Institute (INCA), Rio de Janeiro, Brazil
| | - Edson Toscano
- Department of Thoracic Surgery, Brazilian National Cancer Institute (INCA), Rio de Janeiro, Brazil
| | - Mauro Zamboni
- Department of Thoracic Surgery, Brazilian National Cancer Institute (INCA), Rio de Janeiro, Brazil
| | - Cinthya Sternberg
- Clinical Research Division, Brazilian National Cancer Institute (INCA), Rio de Janeiro, Brazil
| | - Emanuela de Moraes
- Clinical Research Division, Brazilian National Cancer Institute (INCA), Rio de Janeiro, Brazil
| | - José R Lapa E Silva
- Institute of Thoracic Medicine, Clementino Fraga Filho University Hospital, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil
| | - Carlos Gil Ferreira
- National Clinical Cancer Research Network (RNPCC) SCTIE/MS, Rio de Janeiro, Brazil.,D'Or Institute for Research and Education (IDOR), Rio de Janeiro, Brazil
| |
Collapse
|
6
|
Zhu J, Wu C, Li H, Yuan Y, Wang X, Zhao T, Xu J. DACH1 inhibits the proliferation and invasion of lung adenocarcinoma through the downregulation of peroxiredoxin 3. Tumour Biol 2016; 37:9781-8. [PMID: 26810067 PMCID: PMC4990600 DOI: 10.1007/s13277-016-4811-x] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2015] [Accepted: 01/06/2016] [Indexed: 12/14/2022] Open
Abstract
In this study, we found the expression of Dachshund 1 (DACH1) is downregulated while peroxiredoxin 3 (PRX3) upregulated in both lung adenocarcinoma tissues and cells. Transfection of DACH1 can significantly downregulate PRX3 expression in targeting lung adenocarcinoma cells. Further experimental results demonstrated the evidence that overexpression of DACH1 resulted in significant retardation of in vitro proliferation and invasion of lung adenocarcinoma cells. Direct upregulation of PRX3 by co-transfection of PRX3 messenger RNA (mRNA) can prevent the above alteration caused by DACH1 transfection. Besides, lower DACH1 expression significantly correlated with tumor diameter and tumor invasion in all the 36 patients diagnosed with lung adenocarcinoma in our hospital during the past months. In conclusion, DACH1 can inhibit the proliferation and invasion of lung adenocarcinoma through the downregulation of PRX3. Decreased expression of DACH1 is involved in the initiation and development of lung cancer, which might be an adverse prognostic factor of lung adenocarcinoma.
Collapse
Affiliation(s)
- Ji Zhu
- Department of Cardiothoracic Surgery, Changhai Hospital Affiliated to the Second Military Medical University, 168 Changhai Road, 200433, Shanghai, People's Republic of China
| | - Cong Wu
- Department of Laboratory Diagnosis, Changhai Hospital Affiliated to the Second Military Medical University, Shanghai, People's Republic of China
| | - Huafei Li
- International Joint Cancer Institute, Translational Medicine Research Institute, The Second Military Medical University, Shanghai, China
| | - Yang Yuan
- Department of Cardiothoracic Surgery, Changhai Hospital Affiliated to the Second Military Medical University, 168 Changhai Road, 200433, Shanghai, People's Republic of China
| | - Xiaotian Wang
- Department of Cardiothoracic Surgery, Changhai Hospital Affiliated to the Second Military Medical University, 168 Changhai Road, 200433, Shanghai, People's Republic of China
| | - Tiejun Zhao
- Department of Cardiothoracic Surgery, Changhai Hospital Affiliated to the Second Military Medical University, 168 Changhai Road, 200433, Shanghai, People's Republic of China.
| | - Jibin Xu
- Department of Cardiothoracic Surgery, Changzheng Hospital Affiliated to the Second Military Medical University, 415 Fengyang Road, 200433, Shanghai, People's Republic of China.
| |
Collapse
|
7
|
Zhan P, Ji YN, Yu LK. VEGF is associated with the poor survival of patients with prostate cancer: a meta-analysis. Transl Androl Urol 2016; 2:99-105. [PMID: 26816732 PMCID: PMC4708223 DOI: 10.3978/j.issn.2223-4683.2013.06.03] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023] Open
Abstract
Background Vascular endothelial growth factor (VEGF) is considered as a prime mediator of angiogenesis, and has been implicated in carcinogenesis and metastasis. Various studies examined the relationship between VEGF overexpression with the clinical outcome in patients with prostate cancer, but yielded conflicting results. Methods Electronic databases updated to July 2013 were searched to find relevant studies. A meta-analysis was conducted with eligible studies which quantitatively evaluated the relationship between VEGF status and survival of patients with prostate cancer. Survival data were aggregated and quantitatively analyzed. Results We performed a meta-analysis of 9 studies that evaluated the correlation between VEGF overexpression and survival in patients with prostate cancer. Combined hazard ratios suggested VEGF overexpression had an unfavorable impact on overall survival (OS) [hazard ratio (HR) =1.54, 95% CI (confidence interval): 1.25-1.83], but not disease free survival (DFS) (HR=1.23, 95% CI: 0.99-1.47) in patients with prostate cancer. No significant heterogeneity was observed among all studies. Conclusions VEGF overexpression indicates a poor prognosis for patients with prostate cancer.
Collapse
Affiliation(s)
- Ping Zhan
- 1 First Department of Respiratory Medicine, Nanjing Chest Hospital, Nanjing 210029, China ; 2 The Collaborative Research (CORE) Group, Sydney, Australia ; 3 Jiangsu Province Hospital of Traditional Chinese Medicine, Nanjing 210029, China
| | - Ya-Nan Ji
- 1 First Department of Respiratory Medicine, Nanjing Chest Hospital, Nanjing 210029, China ; 2 The Collaborative Research (CORE) Group, Sydney, Australia ; 3 Jiangsu Province Hospital of Traditional Chinese Medicine, Nanjing 210029, China
| | - Li-Ke Yu
- 1 First Department of Respiratory Medicine, Nanjing Chest Hospital, Nanjing 210029, China ; 2 The Collaborative Research (CORE) Group, Sydney, Australia ; 3 Jiangsu Province Hospital of Traditional Chinese Medicine, Nanjing 210029, China
| |
Collapse
|
8
|
Shao W, Chen H, He J. The role of SOX-2 on the survival of patients with non-small cell lung cancer. J Thorac Dis 2015; 7:1113-8. [PMID: 26380725 DOI: 10.3978/j.issn.2072-1439.2015.07.14] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2015] [Accepted: 07/05/2015] [Indexed: 11/14/2022]
Abstract
BACKGROUND Lung cancer is the most commonly diagnosed cancer as well as the leading cause of cancer death worldwide. Observational studies on the prognostic role of SOX-2 in non-small-cell lung cancer (NSCLC) are controversial. METHODS To clarify the impact of SOX-2 in NSCLC survival, we performed this meta-analysis that included eligible studies. The combined hazard ratios and their corresponding 95% confidence intervals (95% CI) were calculated in terms of overall survival. RESULTS A total of seven studies with 1,944 patients were evaluable for this meta-analysis. The studies were categorized by histology, disease stage and patient race. Our results suggested that SOX-2 overexpression had a favorable impact on survival of patients with NSCLC, the HR (95% CI) was 0.57 (0.48 to 0.65). However, highly significant heterogeneity was detected among these studies (I(2)=76.7%, P=0.000). CONCLUSIONS SOX-2 overexpression indicates a favorable prognosis for patients with NSCLC.
Collapse
Affiliation(s)
- Wenlong Shao
- 1 Department of Cardiothoracic Surgery, 2 State Key Laboratory of Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China ; 3 Key Cite of National Clinical Research Center for Respiratory Disease, Guangzhou 510120, China
| | - Hanzhang Chen
- 1 Department of Cardiothoracic Surgery, 2 State Key Laboratory of Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China ; 3 Key Cite of National Clinical Research Center for Respiratory Disease, Guangzhou 510120, China
| | - Jianxing He
- 1 Department of Cardiothoracic Surgery, 2 State Key Laboratory of Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China ; 3 Key Cite of National Clinical Research Center for Respiratory Disease, Guangzhou 510120, China
| |
Collapse
|
9
|
Lv P, Zhang P, Li X, Chen Y. Micro ribonucleic acid (RNA)-101 inhibits cell proliferation and invasion of lung cancer by regulating cyclooxygenase-2. Thorac Cancer 2015; 6:778-84. [PMID: 26557918 PMCID: PMC4632932 DOI: 10.1111/1759-7714.12283] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2015] [Accepted: 05/03/2015] [Indexed: 12/27/2022] Open
Abstract
Background Micro ribonucleic acid (miR-101) can regulate the expression of cyclooxygenase-2 (COX-2) and participate in the pathogenesis of malignant tumors. This study investigates the effects of miRNA-101 and COX-2 in lung cancer and the impact of miR-101 on the proliferation and invasion of human lung cancer A549 cell line. Methods The expression of miR-101 in 20 separate lung cancer tissues was detected by real time polymerase chain reaction; COX-2 expression was also detected. A549 cells were transfected with miR-101 or negative control oligonucleotide duplex mimic (miR-NC). In vivo tumorigenesis abilities were detected in localized human lung cancer xeno-transplant models in BALB/c nude mice. Results MiR-101 expression was significantly lower and the level of COX-2 significantly higher in lung cancer tissues than in adjacent parenchyma (2.918 ± 1.006 vs. 5.953 ± 1.976, P = 0.001; 0.887 ± 0.260 vs. 0.355 ± 0.156, P = 0.001, respectively). Correlation analysis revealed that miR-101 negatively correlated with COX-2 in lung cancer tissues (R = −0.596, P = 0.002). Compared with A549-miR-NC cells, the expression of COX-2 was significantly decreased in A549 cells transfected with miR-101 (P < 0.001). The proliferation of A549 cells was markedly inhibited after transfection of miR-101. The in vivo tumor growth of A549 cells transfected with miR-101 was significantly slower than wide type A549 cells. Conclusion MiR-101 expression is decreased in lung cancer, inducing an increase in COX-2 level. Enforced expression of miR-101 can remarkably reduce the cell proliferation and invasion ability of lung cancer cells.
Collapse
Affiliation(s)
- Peng Lv
- Department of Cardiothoracic Surgery, Tianjin Medical University General Hospital Tianjin, China
| | - Peng Zhang
- Department of Cardiothoracic Surgery, Tianjin Medical University General Hospital Tianjin, China
| | - Xin Li
- Department of Cardiothoracic Surgery, Tianjin Medical University General Hospital Tianjin, China
| | - Yuan Chen
- Department of Cardiothoracic Surgery, Tianjin Medical University General Hospital Tianjin, China
| |
Collapse
|
10
|
Zhou ZJ, Zhan P, Song Y. PD-L1 over-expression and survival in patients with non-small cell lung cancer: a meta-analysis. Transl Lung Cancer Res 2015; 4:203-8. [PMID: 25870804 DOI: 10.3978/j.issn.2218-6751.2015.03.02] [Citation(s) in RCA: 32] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2015] [Accepted: 02/18/2015] [Indexed: 12/20/2022]
Abstract
BACKGROUND Observational studies on the prognostic role of programmed cell death-ligand 1 (PD-L1) in non-small cell lung cancer (NSCLC) are controversial. METHODS To clarify the impact of PD-L1 in NSCLC survival, we performed this meta-analysis that included eligible studies. The combined hazard ratios (HR) and their corresponding 95% confidence intervals (CIs) were calculated in terms of overall survival. RESULTS A total of five studies with 877 patients were evaluable for this meta-analysis. Our results suggested that PD-L1 overexpression had a poor impact on survival of patients with NSCLC, the HR (95% CI) was 1.43 (1.24-1.63) overall, 1.51 (1.24-1.7954) in Asian patients, 1.35 (1.08-1.63) in non-Asian patients. Moreover, there was no heterogeneity between the studies. CONCLUSIONS PD-L1 overexpression indicates a poor prognosis for patients with NSCLC.
Collapse
Affiliation(s)
- Ze-Jun Zhou
- Department of Respiratory Medicine, Jinling Hospital, Nanjing University School of Medical, Nanjing 210002, China
| | - Ping Zhan
- Department of Respiratory Medicine, Jinling Hospital, Nanjing University School of Medical, Nanjing 210002, China
| | - Yong Song
- Department of Respiratory Medicine, Jinling Hospital, Nanjing University School of Medical, Nanjing 210002, China
| |
Collapse
|
11
|
Bhat IA, Rasool R, Qasim I, Masoodi KZ, Paul SA, Bhat BA, Ganaie FA, Aziz SA, Shah ZA. COX-2 overexpression and -8473 T/C polymorphism in 3' UTR in non-small cell lung cancer. Tumour Biol 2014; 35:11209-18. [PMID: 25113252 DOI: 10.1007/s13277-014-2420-0] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2014] [Accepted: 07/29/2014] [Indexed: 01/07/2023] Open
Abstract
A new class of compounds targeting cyclooxygenase 2 (COX-2) together with other different clinically used therapeutic strategies has recently shown a promise for the chemoprevention of several solid tumors including lung cancer. The aim was to study the possible role of COX-2 -8473 T/C NP and its expression in the pathogenesis of non-small cell lung cancer. One hundred ninety non-small cell lung cancer (NSCLC) patients and 200 healthy age-, sex-, and smoking-matched controls were used for polymorphic analysis, and 48 histopathologically confirmed NSCLC patients were analyzed for COX-2 messenger RNA (mRNA) and protein expression. Our results showed that the frequencies of variant genotypes 8473 CT/CC were significantly less common in the cases (30.0%) than in the controls (36%), suggesting that the 8473 C variant allele is related with lower susceptibility in NSCLC (OR = 0.79, 95% CI 0.54-1.4). However, the frequency of COX-2 -8473 TC and CC genotypes were significantly associated with age in NSCLC (P = 0.02). Quantitative real-time expression analysis showed a significant increase in the COX-2 mRNA in tumor tissues as compared to their adjacent normal tissues [delta cycle threshold (ΔCT) = 9.25 ± 4.67 vs 5.63 ± 3.85, P = 0.0001]. Multivariate logistic regression analyses revealed that the COX-2 expression was associated significantly with age (P = 0.044). Also, an increasing trend was observed in stages I and II and in female patients compared to stages III and IV and male patients, respectively, but no statistical significance was observed. However, COX-2 mRNA expression shown no association with the -8473 C variant allele. Our findings indicate that the COX-2 T8473C polymorphism may contribute to NSCLC cancer susceptibility in the Kashmiri population, while our expression analysis revealed a significant increase of COX-2 in tumor tissues as compared to their adjacent normal tissues, suggesting that it could become an important therapeutic marker in NSCLC in the future.
Collapse
Affiliation(s)
- Imtiyaz A Bhat
- Department of Immunology and Molecular Medicine, Sher-I-Kashmir Institute of Medical Sciences, Soura, Srinagar, Kashmir, 190011, India,
| | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Yokouchi H, Kanazawa K, Ishida T, Oizumi S, Shinagawa N, Sukoh N, Harada M, Ogura S, Munakata M, Dosaka-Akita H, Isobe H, Nishimura M. Cyclooxygenase-2 inhibitors for non-small-cell lung cancer: A phase II trial and literature review. Mol Clin Oncol 2014; 2:744-750. [PMID: 25054040 DOI: 10.3892/mco.2014.319] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2014] [Accepted: 05/13/2014] [Indexed: 11/06/2022] Open
Abstract
Several preclinical and clinical studies have demonstrated that cyclooxygenase-2 (COX-2) inhibitors are efficient for the treatment of non-small-cell lung cancer (NSCLC). However, two recent phase III clinical trials using COX-2 inhibitors in combination with platinum-based chemotherapy failed to demonstrate a survival benefit. Thus, validation and discussion regarding the usefulness of COX-2 inhibitors for patients with NSCLC are required. We conducted a prospective trial using COX-2 inhibitors for the treatment of 50 NSCLC patients accrued between April, 2005 and July, 2006. Patients with untreated advanced NSCLC received oral meloxicam (150 mg daily), carboplatin (area under the curve = 5 mg/ml × min on day 1) and docetaxel (60 mg/m2 on day 1) every 3 weeks. The primary endpoint was response rate. The response and disease control rates were 36.0 and 76.0%, respectively. The time-to-progression (TTP) and overall survival (OS) were 5.7 months [95% confidence interval (CI): 4.6-6.7] and 13.7 months (95% CI: 11.4-15.9), respectively. The 1-year survival ratio was 56.0%. Grade 3 neuropathy was observed in only 1 patient. We performed tumor immunohistochemistry for COX-2 and p27 and investigated the correlation between their expression and clinical outcome. COX-2 expression in the tumor tended to correlate with a higher response rate (50.0% in the high- and 18.2% in the low-COX-2 group; P=0.092). Based on our results and previous reports, various trial designs, such as the prospective use of COX-2 inhibitors only for patients with COX-2-positive NSCLC, including the exploratory analysis of biomarkers associated with the COX-2 pathway, may be worth further consideration.
Collapse
Affiliation(s)
- Hiroshi Yokouchi
- Department of Pulmonary Medicine, Fukushima Medical University, Fukushima 960-1295, Japan ; First Department of Medicine, Hokkaido University School of Medicine, Sapporo, Hokkaido 060-8648, Japan
| | - Kenya Kanazawa
- Department of Pulmonary Medicine, Fukushima Medical University, Fukushima 960-1295, Japan
| | - Takashi Ishida
- Department of Pulmonary Medicine, Fukushima Medical University, Fukushima 960-1295, Japan
| | - Satoshi Oizumi
- First Department of Medicine, Hokkaido University School of Medicine, Sapporo, Hokkaido 060-8648, Japan
| | - Naofumi Shinagawa
- First Department of Medicine, Hokkaido University School of Medicine, Sapporo, Hokkaido 060-8648, Japan
| | - Noriaki Sukoh
- Department of Respiratory Medicine, National Hospital Organization Hokkaido Cancer Center, Sapporo, Hokkaido 003-0804, Japan
| | - Masao Harada
- Department of Respiratory Medicine, National Hospital Organization Hokkaido Cancer Center, Sapporo, Hokkaido 003-0804, Japan
| | - Shigeaki Ogura
- Department of Respiratory Disease, Sapporo City General Hospital, Sapporo, Hokkaido 060-8604, Japan
| | - Mitsuru Munakata
- Department of Pulmonary Medicine, Fukushima Medical University, Fukushima 960-1295, Japan
| | - Hirotoshi Dosaka-Akita
- Department of Medical Oncology, Hokkaido University Graduate School of Medicine, Sapporo, Hokkaido 060-8648, Japan
| | - Hiroshi Isobe
- Department of Medical Oncology, KKR Sapporo Medical Center, Sapporo, Hokkaido 062-0931, Japan
| | - Masaharu Nishimura
- First Department of Medicine, Hokkaido University School of Medicine, Sapporo, Hokkaido 060-8648, Japan
| |
Collapse
|
13
|
Ji YN, Wang Q, Li Y, Wang Z. Prognostic value of vascular endothelial growth factor A expression in gastric cancer: a meta-analysis. Tumour Biol 2014; 35:2787-93. [PMID: 24234334 DOI: 10.1007/s13277-013-1371-1] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2013] [Accepted: 10/28/2013] [Indexed: 02/06/2023] Open
Abstract
Vascular endothelial growth factor A (VEGF-A) is considered as a prime mediator of angiogenesis and has been implicated in carcinogenesis and metastasis. Various studies examined the relationship between VEGF-A overexpression with the clinical outcome in patients with gastric cancer, but yielded conflicting results. Electronic databases updated to September 2013 were searched to find relevant studies. A meta-analysis was conducted with eligible studies which quantitatively evaluated the relationship between VEGF-A overexpression and survival of patients with gastric cancer. Survival data were aggregated and quantitatively analyzed. We performed a meta-analysis of 20 studies that evaluated the correlation between VEGF-A overexpression and survival in patients with gastric cancer. Combined hazard ratios suggested that VEGF-A overexpression had an unfavorable impact on overall survival (OS) (hazard ratio [HR] = 1.57; 95% confidence interval [CI], 1.30–1.84) and disease-free survival (DFS) (HR = 1.85; 95% CI, 1.39–2.32) in patients with gastric cancer. No significant heterogeneity (P = 0.487) was observed among 16 studies for OS and among 7 studies for DFS (P = 0.435). VEGF-A overexpression indicates a poor prognosis for overall survival and disease-free survival in patients with gastric cancer.
Collapse
|
14
|
Ji YN, Wang Q, Xue J. TP53 immunohistochemical expression is associated with the poor outcome for hepatocellular carcinoma: evidence from a meta-analysis. Tumour Biol 2014; 35:1653-9. [PMID: 24078450 DOI: 10.1007/s13277-013-1228-7] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2013] [Accepted: 09/17/2013] [Indexed: 12/12/2022] Open
Abstract
Various studies examined the relationship between p53 expression with the clinical outcome in patients with hepatocellular carcinoma (HCC), but yielded conflicting results. Electronic databases updated to July 2013 were searched to find relevant studies. A meta-analysis was conducted with eligible studies which quantitatively evaluated the relationship between p53 expression and survival of patients with HCC. Survival data were aggregated and quantitatively analyzed. We performed a meta-analysis of 24 studies that evaluated the correlation between p53 expression and survival in patients with HCC. Combined hazard ratios suggested that p53 expression had an unfavorable impact on overall survival (OS) (HR (hazard ratio) = 1.55, 95 % CI (confidence interval) 1.36-1.74) and disease-free survival (DFS) (HR = 1.54, 95 % CI 1.21-1.88) in patients with HCC. No significant heterogeneity was observed among 20 studies for OS (P = 0.786) and among 11 studies for DFS (P = 0.698). P53 expression indicates a poor prognosis for patients with hepatocellular carcinoma.
Collapse
|
15
|
Zhan P, Ji YN. Prognostic significance of TP53 expression for patients with hepatocellular carcinoma: a meta-analysis. Hepatobiliary Surg Nutr 2014; 3:11-7. [PMID: 24696834 DOI: 10.3978/j.issn.2304-3881.2014.01.03] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/03/2014] [Accepted: 01/24/2014] [Indexed: 01/01/2023]
Abstract
BACKGROUND Various studies evaluated the relationship between p53 expression and the clinical outcome in patients with hepatocellular carcinoma (HCC), but yielded conflicting results. METHODS Electronic databases updated to Dec 2013 were searched to find relevant studies. A meta-analysis was conducted with eligible studies which quantitatively evaluated the relationship between p53 expression and survival of patients with HCC. Survival data were aggregated and quantitatively analyzed. RESULTS We performed a meta-analysis of 24 studies that evaluated the correlation between p53 expression and survival in patients with HCC. Combined hazard ratios (HRs) suggested that p53 expression had an unfavorable impact on overall survival (OS) [HR =1.64, 95% confidence interval (CI): 1.40-1.85], and disease free survival (DFS) (HR =1.57, 95% CI: 1.26-1.87) in patients with HCC. CONCLUSIONS p53 expression indicates a poor prognosis for patients with HCC.
Collapse
Affiliation(s)
- Ping Zhan
- 1 First Department of Respiratory Medicine, Nanjing Chest Hospital, Nanjing 210029, China ; 2 Jiangsu Province Hospital of Traditional Chinese Medicine, Nanjing 210029, China
| | - Ya-Nan Ji
- 1 First Department of Respiratory Medicine, Nanjing Chest Hospital, Nanjing 210029, China ; 2 Jiangsu Province Hospital of Traditional Chinese Medicine, Nanjing 210029, China
| |
Collapse
|
16
|
Zhan P, Ji YN, Yu LK. TP53 mutation is associated with a poor outcome for patients with hepatocellular carcinoma: evidence from a meta-analysis. Hepatobiliary Surg Nutr 2014; 2:260-5. [PMID: 24570956 DOI: 10.3978/j.issn.2304-3881.2013.07.06] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/24/2013] [Accepted: 07/30/2013] [Indexed: 01/15/2023]
Abstract
BACKGROUND Various studies examined the relationship between p53 mutation with the clinical outcome in patients with hepatocellular carcinoma (HCC), but yielded conflicting results. METHODS Electronic databases updated to July 2013 were searched to find relevant studies. A meta-analysis was conducted with eligible studies which quantitatively evaluated the relationship between p53 mutation and survival of patients with HCC. Survival data were aggregated and quantitatively analyzed. RESULTS We performed a meta-analysis of 9 studies that evaluated the correlation between p53 mutation and survival in patients with HCC. Combined hazard ratios suggested that p53 mutation had an unfavorable impact on overall survival (OS) [hazard ratio (HR) =1.46, 95% confidence interval (CI): 1.15-1.76], and disease free survival (DFS) (HR =2.57, 95% CI: 1.46-3.68) in patients with HCC. The significant heterogeneity (P=0.035) was observed among 8 studies for OS, however no significant heterogeneity (P=0.597) was observed among 5 studies for DFS. CONCLUSIONS p53 mutation indicates a poor prognosis for patients with hepatocellular carcinoma.
Collapse
Affiliation(s)
- Ping Zhan
- First Department of Respiratory Medicine, Nanjing Chest Hospital, Nanjing 210029, China; ; The Collaborative Research (CORE) Group, Sydney, Australia
| | - Ya-Nan Ji
- Jiangsu Province Hospital of Traditional Chinese Medicine, Nanjing 210029, China
| | - Li-Ke Yu
- First Department of Respiratory Medicine, Nanjing Chest Hospital, Nanjing 210029, China
| |
Collapse
|
17
|
Zhan P, Qian Q, Yu LK. Prognostic significance of vascular endothelial growth factor expression in hepatocellular carcinoma tissue: a meta-analysis. Hepatobiliary Surg Nutr 2014; 2:148-55. [PMID: 24570933 DOI: 10.3978/j.issn.2304-3881.2013.06.06] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/01/2013] [Accepted: 06/21/2013] [Indexed: 12/27/2022]
Abstract
BACKGROUND Vascular endothelial growth factor (VEGF) is considered as a prime mediator of angiogenesis, and has been implicated in carcinogenesis and metastasis. Various studies examined the relationship between VEGF overexpression with the clinical outcome in patients with hepatocellular carcinoma (HCC), but yielded conflicting results. METHODS Electronic databases updated to June 2013 were searched to find relevant studies. A meta-analysis was conducted with eligible studies which quantitatively evaluated the relationship between VEGF overexpression and survival of patients with HCC. Survival data were aggregated and quantitatively analyzed. RESULTS We performed a meta-analysis of 14 studies that evaluated the correlation between VEGF overexpression and survival in patients with HCC. Combined hazard ratios suggested that VEGF overexpression had an unfavorable impact on overall survival (OS) [hazard ratio (HR) =1.42, 95% confidence interval (CI): 1.42-1.7], but not disease free survival (DFS) (HR=1.13, 95% CI: 0.89-1.38) in patients with HCC. No significant heterogeneity (P=0.949) was observed among 9 studies for OS, however significant heterogeneity (P=0.008) was observed among 11 studies for DFS. CONCLUSIONS VEGF overexpression indicates a poor prognosis for patients with HCC.
Collapse
Affiliation(s)
- Ping Zhan
- First Department of Respiratory Medicine, Nanjing Chest Hospital, Nanjing 210029, China; ; The Collaborative Research (CORE) Group, Sydney, Australia
| | - Qian Qian
- First Department of Respiratory Medicine, Nanjing Chest Hospital, Nanjing 210029, China
| | - Li-Ke Yu
- First Department of Respiratory Medicine, Nanjing Chest Hospital, Nanjing 210029, China
| |
Collapse
|
18
|
Zhan P, Qian Q, Yu LK. Serum VEGF level is associated with the outcome of patients with hepatocellular carcinoma: a meta-analysis. Hepatobiliary Surg Nutr 2014; 2:209-15. [PMID: 24570945 DOI: 10.3978/j.issn.2304-3881.2013.06.07] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/08/2013] [Accepted: 06/28/2013] [Indexed: 12/24/2022]
Abstract
BACKGROUND Hepatocellular carcinoma (HCC) is a highly vascular tumor that expresses vascular endothelial growth factor (VEGF). Various studies have evaluated the prognostic value of VEGF levels in HCC, but yielded conflicting results. METHODS Electronic databases updated to June 2013 were searched to find relevant studies. A meta-analysis was conducted with eligible studies which quantitatively evaluated the relationship between serum VEGF level and survival of patients with HCC. Survival data were aggregated and quantitatively analyzed. RESULTS We performed a meta-analysis of 11 studies that evaluated the correlation between serum VEGF level and survival in patients with HCC. Combined hazard ratios suggested that serum VEGF level had an unfavorable impact on overall survival (OS) [hazard ratio (HR) =1.88, 95% confidence interval (CI): 1.46-2.30], and disease free survival (DFS) (HR=2.27, 95% CI: 1.55-2.98) in patients with HCC. No significant heterogeneity was observed among all studies. CONCLUSIONS Serum high VEGF level indicates a poor prognosis for patients with hepatocellular carcinoma.
Collapse
Affiliation(s)
- Ping Zhan
- First Department of Respiratory Medicine, Nanjing Chest Hospital, Nanjing 210029, China; ; The Collaborative Research (CORE) Group, Sydney, Australia
| | - Qian Qian
- First Department of Respiratory Medicine, Nanjing Chest Hospital, Nanjing 210029, China
| | - Li-Ke Yu
- First Department of Respiratory Medicine, Nanjing Chest Hospital, Nanjing 210029, China
| |
Collapse
|
19
|
Xu CH, Wang Q, Zhan P, Qian Q, Yu LK. GSTP1 Ile105Val polymorphism is associated with lung cancer risk among Asian population and smokers: an updated meta-analysis. Mol Biol Rep 2014; 41:4199-212. [PMID: 24566690 DOI: 10.1007/s11033-014-3290-7] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2013] [Accepted: 02/13/2014] [Indexed: 11/25/2022]
Abstract
Many studies have examined the association between the GSTP1 Ile105Val (rs 1695) gene polymorphism and lung cancer risk in various populations, but their results have been inconsistent. To assess this relationship more precisely, a meta-analysis was performed. The PubMed and CNKI database was searched for case-control studies published up to July 2012. Data were extracted and pooled odds ratios (OR) with 95% confidence intervals (CI) were calculated. Ultimately, 42 studies, comprising 12,304 lung cancer cases and 15,729 controls were included. Overall, for G allele carriers (GA + GG) versus homozygote AA, the pooled OR was 1.05 (95% CI 0.99-1.10 P = 0.092 for heterogeneity), for GG versus AA the pooled OR was 1.04 (95% CI 0.96-1.12 P = 0.084 for heterogeneity). In the stratified analysis by ethnicity, gender, histological types of lung cancer and smoking status, a significant association was found in Asians and smokers, not in Caucasian or mixed population, Male, Female population, lung AC, SCC, SCLC or non-smokers. Publication bias was found by using the funnel plot and Egger's test. Overall, there is no evidence showing a significant correlation between GSTP1 Ile105Val gene polymorphism and lung cancer risk in overall population, however stratified analysis by ethnicity, histology, gender and smoking status, it correlate with increased lung cancer susceptibility among Asians and smokers.
Collapse
Affiliation(s)
- Chun-hua Xu
- First Department of Respiratory Medicine, Nanjing Chest Hospital, 215 Guangzhou Road, Nanjing, 210029, China
| | | | | | | | | |
Collapse
|
20
|
The Role of Inflammation in Lung Cancer. ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY 2014; 816:1-23. [DOI: 10.1007/978-3-0348-0837-8_1] [Citation(s) in RCA: 150] [Impact Index Per Article: 15.0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
|
21
|
Wang Z, He M, Xiao Z, Wu H, Wu Y. Quantitative assessment of the association of COX-2 (Cyclooxygenase-2) immunoexpression with prognosis in human osteosarcoma: a meta-analysis. PLoS One 2013; 8:e82907. [PMID: 24358237 PMCID: PMC3865095 DOI: 10.1371/journal.pone.0082907] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2013] [Accepted: 10/28/2013] [Indexed: 12/30/2022] Open
Abstract
Background Numerous studies examining the relationship between Cyclooxygenase-2 (COX-2) immunoexpression and clinical outcome in osteosarcoma patients have yielded inconclusive results. Methods We accordingly conducted a meta-analysis of 9 studies (442 patients) that evaluated the correlation between COX-2 immunoexpression and clinical prognosis (death). Pooled odds ratios (OR) and risk ratios (RR) with 95% confidence intervals (95% CI) were calculated using the random-effects or fixed-effects model. Results Meta–analysis showed no significant association between COX-2 positivity and age, gender, tumor location, histology, stage, metastasis or 90% necrosis. Conversely, COX-2 immunoexpression was associated with overall survival rate (RR=2.12; 95% CI: 1.10–3.74; P=0.009) and disease-free survival rate (RR=1.63; 95% CI: 1.17–2.28; P=0.004) at 2 years. Sensitivity analysis performed by omitting low quality studies showed that the pooled results were stable. Conclusions COX-2 positivity was associated with a lower 2-year overall survival rate and disease-free survival rate. COX-2 expression change is an independent prognostic factor in patients with osteosarcoma.
Collapse
Affiliation(s)
- Zhe Wang
- Division of Spine and Osteopathy Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China
| | - Maolin He
- Division of Spine and Osteopathy Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China
| | - Zengming Xiao
- Division of Spine and Osteopathy Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China
- * E-mail:
| | - Hao Wu
- Division of Spine and Osteopathy Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China
| | - Yang Wu
- Division of Spine and Osteopathy Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China
| |
Collapse
|
22
|
Chen W, Wang Q, Liu M, Ding XB. The association of APE1 Asp148Glu gene polymorphisms and lung cancer risk: an updated meta-analysis. Tumour Biol 2013; 35:3597-603. [PMID: 24310503 DOI: 10.1007/s13277-013-1474-8] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2013] [Accepted: 11/26/2013] [Indexed: 12/31/2022] Open
Abstract
Many studies have examined the association between APE1 Asp148Glu (rs3136820) polymorphism gene polymorphisms and lung cancer risk in various populations, but their results have been inconsistent. To assess this relationship more precisely, a meta-analysis was performed. PubMed and CNKI databases were searched for case-control studies published up to October 2013. Data were extracted, and pooled odds ratios (OR) with 95% confidence intervals (CI) were calculated. Ultimately, 14 studies, comprising 4,165 lung cancer cases and 5,438 controls were included. Overall, for Glu carriers (Asp/Glu + Glu/Glu) versus wild-type homozygotes (Asp/Asp), the pooled OR was 1.05 (95% CI = 0.96-1.15 P = 0.000 for heterogeneity); for Glu/Glu versus Asp/Asp, the pooled OR was 1.07 (95% CI = 0.95-1.21 P = 0.007 for heterogeneity). In the stratified analysis by ethnicity, the significantly risks were not found among Asians or Caucasians. This updated meta-analysis suggests that the APE1 Asp148Glu polymorphisms are not associated with lung cancer risk among Asians or Caucasians.
Collapse
Affiliation(s)
- Wen Chen
- Shanghai Xujiahui Community Medical Service Center, Shanghai, 200030, China
| | | | | | | |
Collapse
|
23
|
Domvri K, Zarogoulidis P, Darwiche K, Browning RF, Li Q, Turner JF, Kioumis I, Spyratos D, Porpodis K, Papaiwannou A, Tsiouda T, Freitag L, Zarogoulidis K. Molecular Targeted Drugs and Biomarkers in NSCLC, the Evolving Role of Individualized Therapy. J Cancer 2013; 4:736-54. [PMID: 24312144 PMCID: PMC3842443 DOI: 10.7150/jca.7734] [Citation(s) in RCA: 71] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2013] [Accepted: 11/12/2013] [Indexed: 01/08/2023] Open
Abstract
Lung cancer first line treatment has been directed from the non-specific cytotoxic doublet chemotherapy to the molecular targeted. The major limitation of the targeted therapies still remains the small number of patients positive to gene mutations. Furthermore, the differentiation between second line and maintenance therapy has not been fully clarified and differs in the clinical practice between cancer centers. The authors present a segregation between maintenance treatment and second line and present a possible definition for the term “maintenance” treatment. In addition, cancer cell evolution induces mutations and therefore either targeted therapies or non-specific chemotherapy drugs in many patients become ineffective. In the present work pathways such as epidermal growth factor, anaplastic lymphoma kinase, met proto-oncogene and PI3K are extensively presented and correlated with current chemotherapy treatment. Future, perspectives for targeted treatment are presented based on the current publications and ongoing clinical trials.
Collapse
Affiliation(s)
- Kalliopi Domvri
- 1. Pulmonary Department-Oncology Unit, "G. Papanikolaou" General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
24
|
VEGF +936C/T and +460C/T gene polymorphisms and oral cancer risk: a meta-analysis. Mol Biol Rep 2013; 40:6637-43. [PMID: 24057253 DOI: 10.1007/s11033-013-2778-x] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2013] [Accepted: 09/14/2013] [Indexed: 10/26/2022]
Abstract
Many studies have examined the association between the VEGF +936C/T (rs833061) and +460C/T (rs3025039) gene polymorphisms and oral cancer risk in various populations, but their results have been inconsistent. To assess this relationship more precisely, we performed a meta-analysis. The PubMed, Embase, Web of Science, and China National Knowledge Infrastructure databases were searched for case-control studies that were published up to January 2013. Data were extracted and pooled odds ratios (ORs) with 95 % confidence intervals (CIs) were calculated. Ultimately, six studies were included, comprising 1006 oral cancer cases and 1016 controls. Overall, the pooled OR for VEGF +936 T allele carriers (TC + TT) versus the wild-type homozygotes (CC) was 1.28 (95 % CI 1.04-1.58; P = 0.228 for heterogeneity), the pooled OR for TT versus CC was 1.64 (95 % CI 1.34-1.98; P = 0.315 for heterogeneity), and the pooled OR for the T allele versus the C allele was 1.42 (95 % CI 1.22-1.76; P = 0.286 for heterogeneity). In the stratified analysis by ethnicity, significant risks were found among Caucasians but not Asians. However, there were no associations between VEGF +460C/T and oral cancer risk in only two of the included studies. In conclusion, this meta-analysis demonstrates that the VEGF +936 T allele may be associated with an increased risk of oral cancer, especially among Caucasian populations.
Collapse
|
25
|
Yu XW, Wu TY, Yi X, Ren WP, Zhou ZB, Sun YQ, Zhang CQ. Prognostic significance of VEGF expression in osteosarcoma: a meta-analysis. Tumour Biol 2013; 35:155-60. [PMID: 23907576 DOI: 10.1007/s13277-013-1019-1] [Citation(s) in RCA: 51] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2013] [Accepted: 07/11/2013] [Indexed: 01/21/2023] Open
Abstract
Vascular endothelial growth factor (VEGF) is considered as a prime mediator of angiogenesis and has been implicated in carcinogenesis and metastasis. Various studies examined the relationship between VEGF overexpression with the clinical outcome in patients with osteosarcoma but yielded conflicting results. Electronic databases updated to April 2013 were searched to find relevant studies. A meta-analysis was conducted with eligible studies which quantitatively evaluated the relationship between VEGF overexpression and survival of patients with osteosarcoma. Survival data were aggregated and quantitatively analyzed. We performed a meta-analysis of eight studies that evaluated the correlation between VEGF overexpression and survival in patients with osteosarcoma. Combined hazard ratios suggested that VEGF overexpression had an unfavorable impact on overall survival (hazard ratio (HR) = 1.75, 95% confidence interval (CI): 1.21-2.28) in patients with osteosarcoma for overall populations, 2.37 (1.35-3.39) in Asian studies but not in non-Asian studies (HR = 1.51, 95% CI: 0.89-2.14). No significant heterogeneity was observed among all studies. VEGF overexpression indicates a poor prognosis for patients with osteosarcoma. However, the prognostic value of VEGF on survival in osteosarcoma patients still needs further large-scale prospective trials to be clarified.
Collapse
Affiliation(s)
- Xiao-Wei Yu
- Department of Orthopaedics, Shanghai Sixth People's Hospital, Shanghai Jiaotong University, Shanghai, 200011, China
| | | | | | | | | | | | | |
Collapse
|
26
|
GSTM1 null polymorphisms and oral cancer risk: a meta-analysis. Tumour Biol 2013; 35:287-93. [PMID: 23900674 DOI: 10.1007/s13277-013-1037-z] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2013] [Accepted: 07/18/2013] [Indexed: 12/24/2022] Open
Abstract
Many studies have examined the association between the GSTM1 null gene polymorphism and oral cancer risk in various populations, but their results have been inconsistent. To assess this relationship more precisely, a meta-analysis was performed. The PubMed and Embase databases were searched for case-control studies published up to May 2013. Data were extracted and pooled odds ratio (OR) with 95% confidence intervals (CI) were calculated. Ultimately, 39 studies, comprising of 4,704 oral cancer cases and 7,090 controls, were included. Overall, for null versus present, the pooled OR was 1.29 (95% CI = 1.20-1.40), and the heterogeneity was found in all studies. In the stratified analysis by ethnicity, significant risks were found among Asians (OR = 1.39, 95% CI = 1.27-1.53; P = 0.000 for heterogeneity), but not in Caucasians (OR = 0.99, 95% CI = 0.83-1.18; P = 0.677 for heterogeneity). In conclusion, this meta-analysis demonstrates that the GSTM1 null gene polymorphism may be an increased risk of oral cancer in Asians but not in Caucasians.
Collapse
|
27
|
Wang Y, Wang D, Ren M. Prognostic value of HER-2/neu expression in epithelial ovarian cancer: a meta-analysis. Tumour Biol 2013; 35:33-8. [PMID: 23873100 DOI: 10.1007/s13277-013-1003-9] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/05/2013] [Accepted: 07/04/2013] [Indexed: 12/11/2022] Open
Abstract
Various studies examined the relationship between human epidermal growth factor receptor 2 (HER-2/neu) overexpression and the clinical outcome in patients with ovarian cancer, but yielded conflicting results. Electronic databases updated in May 2013 were searched to find relevant studies. A meta-analysis was conducted with eligible studies which quantitatively evaluated the relationship between HER-2/neu overexpression and survival of patients with ovarian cancer. Survival data were aggregated and quantitatively analyzed. We conducted a final analysis of 3,055 patients from 20 eligible studies and evaluated the correlation between HER-2/neu overexpression and survival in patients with ovarian cancer. Combined hazard ratios suggested that HER-2/neu overexpression was not associated with a significant impact on survival, with the hazard ratio (HR) and 95% confidence interval (CI) being 1.05 and 0.92-1.19, respectively, overall. When grouped according to the study design type, a statistically significant combined HR was found in retrospective studies (HR = 1.44, 95% CI 1.14-1.75) and no statistically significant combined HR was found (HR = 0.96, 95% CI 0.81-1.11) for prospective studies. HER-2/neu overexpression seems to have no significant impact on survival of ovarian cancer patients. However, a statistically significant combined HR was found in retrospective studies, but not in prospective studies.
Collapse
Affiliation(s)
- Yan Wang
- Department of Obstetrics and Gynecology, Zhongda Hospital, Southeast University, Nanjing, 210009, China
| | | | | |
Collapse
|
28
|
Xu CH, Wang Q, Qian Q, Zhan P, Yu LK. CYP1A1 exon7 polymorphism is associated with lung cancer risk among the female population and among smokers: a meta-analysis. Tumour Biol 2013; 34:3901-11. [PMID: 23832578 DOI: 10.1007/s13277-013-0978-6] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2013] [Accepted: 06/25/2013] [Indexed: 01/09/2023] Open
Abstract
The genetic polymorphism of the CYP1A1 exon7 (rs1048943) gene is thought to have a significant effect on lung cancer risk, but the results are inconsistent. To assess this relationship more precisely, a meta-analysis was performed. Ultimately, 45 case-control studies, involving 19,689 subjects were included. A significantly increased lung cancer risk was associated with two exon7 genotype variants (for Val/Val vs Ile/Ile: odds ratio [OR] = 1.23, 95% confidence interval [CI] = 1.10-1.43; for (Ile/Val + Val/Val) vs Ile/Ile: OR = 1.16, 95% CI = 1.08-1.24) in the overall population. In the stratified analysis by ethnicity, gender, and smoking status, a significant association was found in Asians, Caucasians, and the female population, not the male population. Additionally, a significant association was found in the smoker population, not in the nonsmoker population. This meta-analysis suggests that the exon7 polymorphisms of CYP1A1 correlate with increased lung cancer susceptibility and there is an interaction between CYP1A1 exon7 polymorphisms and smoking, but these associations vary in different genders of the case and control populations.
Collapse
Affiliation(s)
- Chun-hua Xu
- First Department of Respiratory Medicine, Nanjing Chest Hospital, Nanjing, China
| | | | | | | | | |
Collapse
|